Literature DB >> 10469636

Induction of cyclin-dependent kinase inhibitors and G(1) prolongation by the chemopreventive agent N-acetylcysteine.

M Liu1, N M Wikonkal, D E Brash.   

Abstract

Cyclin-dependent kinase (cdk) inhibitors, such as p16(INK4a) and p21(WAF1/CIP1), often inhibit G(1) cyclin kinases and result in G(1) arrest. It has been suggested that p21(WAF1/CIP1) may also play a role in other chemopreventive activities such as DNA repair, slowdown of DNA replication and induction of cellular differentiation. In this report we demonstrate that the antioxidant N-acetylcysteine (NAC), a well-known chemopreventive agent, induces p16(INK4a) and p21(WAF1/CIP1) gene expression and prolongs cell-cycle transition through G(1) phase. A portion of the G(1) arrest by NAC is governed by p16(INK4a); it is independent of p53. NAC's usual mechanism of increasing intracellular glutathione level is not required for the G(1) arrest. An antioxidant whose action is limited to scavenging radicals, Trolox, does not induce G(1) arrest. Taken together, these results suggest a potential novel molecular basis for chemoprevention by NAC.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10469636     DOI: 10.1093/carcin/20.9.1869

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  10 in total

1.  The antioxidant n-acetylcysteine increases 5-fluorouracil activity against colorectal cancer xenografts in nude mice.

Authors:  S P Bach; S E Williamson; E Marshman; S Kumar; S T O'Dwyer; C S Potten; A J Watson
Journal:  J Gastrointest Surg       Date:  2001 Jan-Feb       Impact factor: 3.452

2.  p16 Modulates VEGF expression via its interaction with HIF-1alpha in breast cancer cells.

Authors:  Jun Zhang; Andrew Lu; Liyuan Li; Junming Yue; Yi Lu
Journal:  Cancer Invest       Date:  2010-07       Impact factor: 2.176

3.  Chemoprevention by N-acetylcysteine of low-dose CT-induced murine lung tumorigenesis.

Authors:  Mark Steven Miller; Joseph E Moore; Matthew C Walb; Nancy D Kock; Albert Attia; Scott Isom; Jennifer E McBride; Michael T Munley
Journal:  Carcinogenesis       Date:  2012-10-26       Impact factor: 4.944

Review 4.  Redox control of the cell cycle in health and disease.

Authors:  Ehab H Sarsour; Maneesh G Kumar; Leena Chaudhuri; Amanda L Kalen; Prabhat C Goswami
Journal:  Antioxid Redox Signal       Date:  2009-12       Impact factor: 8.401

5.  Mifepristone inhibits ovarian cancer cell growth in vitro and in vivo.

Authors:  Alicia A Goyeneche; Rubén W Carón; Carlos M Telleria
Journal:  Clin Cancer Res       Date:  2007-06-01       Impact factor: 12.531

6.  Antiprogestin mifepristone inhibits the growth of cancer cells of reproductive and non-reproductive origin regardless of progesterone receptor expression.

Authors:  Chelsea R Tieszen; Alicia A Goyeneche; BreeAnn N Brandhagen; Casey T Ortbahn; Carlos M Telleria
Journal:  BMC Cancer       Date:  2011-05-27       Impact factor: 4.430

Review 7.  Antiprogestins in gynecological diseases.

Authors:  Alicia A Goyeneche; Carlos M Telleria
Journal:  Reproduction       Date:  2014-09-24       Impact factor: 3.906

8.  Bromelain and N-acetylcysteine inhibit proliferation and survival of gastrointestinal cancer cells in vitro: significance of combination therapy.

Authors:  Afshin Amini; Samar Masoumi-Moghaddam; Anahid Ehteda; David Lawson Morris
Journal:  J Exp Clin Cancer Res       Date:  2014-11-12

Review 9.  The Use of Genetically Engineered Mouse Models for Studying the Function of Mutated Driver Genes in Pancreatic Cancer.

Authors:  Ching-Chieh Weng; Yu-Chun Lin; Kuang-Hung Cheng
Journal:  J Clin Med       Date:  2019-09-02       Impact factor: 4.241

10.  NAC, tiron and trolox impair survival of cell cultures containing glioblastoma tumorigenic initiating cells by inhibition of cell cycle progression.

Authors:  Massimiliano Monticone; Razieh Taherian; Sara Stigliani; Elisa Carra; Stefano Monteghirfo; Luca Longo; Antonio Daga; Mariella Dono; Simona Zupo; Walter Giaretti; Patrizio Castagnola
Journal:  PLoS One       Date:  2014-02-28       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.